The average P/S ratio for RNA's competitors is 153.26, providing a benchmark for relative valuation. Avidity Biosciences Inc Corp (RNA) exhibits a P/S ratio of 587.65, which is 283.43% above the industry average. Given its robust revenue growth of -55.60%, this premium appears unsustainable.